Editas Medicine (EDIT) Share-based Compensation (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Share-based Compensation of $2.2 million for Q3 2025, down 53.6% year-over-year from $4.8 million in Q3 2024, and down 16.37% quarter-over-quarter from $2.7 million in Q2 2025.
Editas Medicine (EDIT) Share-based Compensation (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Share-based Compensation for 11 consecutive years, with $2.2 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Share-based Compensation fell 53.6% year-over-year to $2.2 million; the TTM figure through Sep 2025 stood at $11.9 million (down 47.71% YoY), while the FY2024 annual figure was $21.4 million, up 8.18% from the prior year.
- Share-based Compensation retreated to $2.2 million in Q3 2025 per EDIT's latest filing, from $2.7 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $37.0 million in Q3 2022 and bottomed at $526000.0 in Q2 2021.
- Historically, Share-based Compensation has averaged $7.4 million across 5 years, with a median of $5.2 million in 2023.
- Annual changes were most pronounced in 2022 — Share-based Compensation soared 1158.17% — and 2023, when it plunged 87.21%.
- Editas Medicine's Share-based Compensation stood at $7.7 million in 2021, then retreated by 29.95% to $5.4 million in 2022, then declined by 0.35% to $5.3 million in 2023, then dropped by 24.79% to $4.0 million in 2024, then sank by 44.58% to $2.2 million in 2025.
- Business Quant data shows EDIT's Share-based Compensation at $2.2 million in Q3 2025, $2.7 million in Q2 2025, and $3.0 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 2.23 Mn |
| Sep 30, 2025 | 2.23 Mn |
| Jun 30, 2025 | 2.66 Mn |
| Jun 30, 2025 | 2.66 Mn |
| Mar 31, 2025 | 2.98 Mn |
| Mar 31, 2025 | 2.98 Mn |
| Dec 31, 2024 | 4.02 Mn |
| Dec 31, 2024 | 4.02 Mn |
| Sep 30, 2024 | 4.80 Mn |
| Sep 30, 2024 | 4.80 Mn |
| Jun 30, 2024 | 5.01 Mn |
| Jun 30, 2024 | 5.01 Mn |
| Mar 31, 2024 | 7.59 Mn |
| Mar 31, 2024 | 7.59 Mn |
| Dec 31, 2023 | 5.35 Mn |
| Dec 31, 2023 | 5.35 Mn |
| Sep 30, 2023 | 4.73 Mn |
| Sep 30, 2023 | 4.73 Mn |
| Jun 30, 2023 | 5.22 Mn |
| Jun 30, 2023 | 5.22 Mn |